CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 59,510 enrolled
Drug / intervention
Drospirenone +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00302848
NCT00302848N/ACompleted

The European Active Surveillance Study on OC Prescribing Practice, Benefits and Safety (EURAS)

Center for Epidemiology and Health Research, Germany·observational·Posted Mar 15, 2006·Updated Nov 20, 2009

In Brief

An observational study evaluating Drospirenone, Levonorgestrel, and 1 other intervention for Contraception. Completed, enrolled 59,510 participants across 1 site.

Detailed Summary

EURAS is a multi-national, controlled, prospective, post-marketing, non-intervention cohort study of new users of drospirenone/ethinylestradiol (DRSP/EE), levonorgestrel/ethinylestradiol (LNG/EE) and other oral contraceptives (OCs) under routine conditions of medical practice in seven European countries. Baseline survey and semiannual, active follow-up are based on postal questionnaires, with validation of reported events by the women's treating physicians. A multifaceted 4-level follow-up procedure will be established to ensure low loss to follow-up rates. The objective of the study is the investigation of the incidence of rare serious adverse events associated with the use of new and established OCs, and specifically the incidence of thromboembolic events.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsContraception
CountriesGermany

Timeline

N/ACompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 15, 2006
Enrollment StartNov 1, 2000
Study CompletionDec 1, 2005
TodayJul 2, 2026
Posted 20.3 years ago

Interventions

Drospirenonedrug

Levonorgestreldrug

Other progestin containing oral contraceptivedrug